Editor’ note:  Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA). Discuss your use of THC, Cannabis or CBD products with your health care provider.  Dosing of Cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles, drinks and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products. MedicalResearch.com Interview with: Prof. Joseph (Yossi) Tam, DMD, PhDSchool of Pharmacy, Institute for Drug Research The Hebrew University of Jerusalem The Harvey M. Krueger Family Center for Nanoscience and Nanotechnology Jerusalem, Israel With colleagues Dr. Liad Hinden, the PhD student Radka Kočvarová, and the Tam’s team at the School of Pharmacy at the Faculty of Medicine of the Hebrew University of Jerusalem.   MedicalResearch.com: What is the background for this study? Would you describe the condition of Metabolic dysfunction-associated steatotic liver disease (MASLD)? What causes it? Whom does it affect? Response: MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disorder worldwide. It develops when fat accumulates excessively in liver cells, commonly in people with obesity, insulin resistance, high cholesterol, or diabetes. Over time, this condition can progress to inflammation, fibrosis, or cirrhosis. Despite its growing prevalence, effective pharmacological therapies remain limited, leaving a substantial unmet clinical need.